News09.12.2025
MedTech Virtonomy has secured €5 million in Series A funding
Munich-based health tech company Virtonomy, which pioneers virtual patient twins for digital clinical trials, has successfully closed its Series A financing round, raising over €5 million. The round was led by Companisto, the largest business angel network in the DACH region, with strong participation from Bayern Kapital and other institutional investors, underscoring the strong confidence in Virtonomy’s technology and long-term vision.
High investor demand resulted in an increase in the size of the round, reflecting the growing interest in scalable, data-driven solutions for clinical validation. Virtonomy has previously attracted prominent global venture investors, including Accenture Ventures, Dieter von Holtzbrinck Ventures, Honeystone Ventures, Pace Ventures, UnternehmerTUM and Plug & Play.
Virtonomy’s platform allows medical device manufacturers to test and validate their products using virtual patient twins based on real-world clinical data. This approach eliminates the need for animal studies and substantially shortens conventional clinical timelines, reducing time-to-market by up to 40% while delivering significant cost efficiencies. More than 25 international MedTech companies, including Medtronic, Johnson & Johnson, and Boston Scientific, already rely on Virtonomy’s technology.
„DvH Ventures has been supporting Virtonomy since its seed round. From the start, the platform stood out for addressing a central challenge in medtech: the costly and complex process of clinical studies, including animal and human testing. The simulation software enables for faster and more efficient product development and significantly shortens time-to-market for medical device manufacturers. This strong positioning in a key industry makes the company a highly promising, scalable investment for us.”
The new capital will support the international expansion of the platform, the further development of regulatory pathways, and the company's growth into additional markets. Virtonomy aims to establish the world's leading infrastructure for digital clinical studies.
„By successfully closing our Series A financing round, we are laying the foundation to further scale the Virtonomy platform internationally, intensify regulatory validation and enter additional markets. The strong support from our investors confirms the relevance of data-driven virtual patients as a reliable alternative to lengthy clinical studies and animal testing. Our vision is for every medical device worldwide to reach the market faster, more safely and efficiently through the use of our digital patient twins.“
With strengthened financial backing and a clear pathway for global expansion, Virtonomy is well-placed to drive the digital transformation of clinical evidence generation across the MedTech industry.